These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16326923)

  • 1. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.
    Dawson GR; Maubach KA; Collinson N; Cobain M; Everitt BJ; MacLeod AM; Choudhury HI; McDonald LM; Pillai G; Rycroft W; Smith AJ; Sternfeld F; Tattersall FD; Wafford KA; Reynolds DS; Seabrook GR; Atack JR
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1335-45. PubMed ID: 16326923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
    Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
    Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
    Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
    Atack JR
    Pharmacol Ther; 2010 Jan; 125(1):11-26. PubMed ID: 19770002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.
    Collinson N; Atack JR; Laughton P; Dawson GR; Stephens DN
    Psychopharmacology (Berl); 2006 Nov; 188(4):619-28. PubMed ID: 16633803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
    Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition.
    Chambers MS; Atack JR; Broughton HB; Collinson N; Cook S; Dawson GR; Hobbs SC; Marshall G; Maubach KA; Pillai GV; Reeve AJ; MacLeod AM
    J Med Chem; 2003 May; 46(11):2227-40. PubMed ID: 12747794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats.
    Savić MM; Clayton T; Furtmüller R; Gavrilović I; Samardzić J; Savić S; Huck S; Sieghart W; Cook JM
    Brain Res; 2008 May; 1208():150-9. PubMed ID: 18394590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer.
    Atack JR
    CNS Neurosci Ther; 2008; 14(1):25-35. PubMed ID: 18482097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
    Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
    J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABA
    Duchon A; Gruart A; Albac C; Delatour B; Zorrilla de San Martin J; Delgado-García JM; Hérault Y; Potier MC
    Br J Pharmacol; 2020 Mar; 177(5):1106-1118. PubMed ID: 31652355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONO-8590580, a Novel GABA
    Kawaharada S; Nakanishi M; Nakanishi N; Hazama K; Higashino M; Yasuhiro T; Lewis A; Clark GS; Chambers MS; Maidment SA; Katsumata S; Kaneko S
    J Pharmacol Exp Ther; 2018 Jul; 366(1):58-65. PubMed ID: 29674331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential role of alpha1- and alpha5-containing GABA(A) receptors in mediating diazepam effects on spontaneous locomotor activity and water-maze learning and memory in rats.
    Savić MM; Milinković MM; Rallapalli S; Clayton T; Joksimović S; Van Linn M; Cook JM
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1179-93. PubMed ID: 19265570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging.
    Eng W; Atack JR; Bergstrom M; Sanabria S; Appel L; Dawson GR; Sciberras D; Hargreaves RJ; Langstrom B; Burns HD
    Neuropharmacology; 2010 Dec; 59(7-8):635-9. PubMed ID: 20696179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basmisanil, a highly selective GABA
    Hipp JF; Knoflach F; Comley R; Ballard TM; Honer M; Trube G; Gasser R; Prinssen E; Wallace TL; Rothfuss A; Knust H; Lennon-Chrimes S; Derks M; Bentley D; Squassante L; Nave S; Nöldeke J; Wandel C; Thomas AW; Hernandez MC
    Sci Rep; 2021 Apr; 11(1):7700. PubMed ID: 33833333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors.
    Atack JR; Hutson PH; Collinson N; Marshall G; Bentley G; Moyes C; Cook SM; Collins I; Wafford K; McKernan RM; Dawson GR
    Br J Pharmacol; 2005 Feb; 144(3):357-66. PubMed ID: 15655523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
    Chambers MS; Atack JR; Carling RW; Collinson N; Cook SM; Dawson GR; Ferris P; Hobbs SC; O'connor D; Marshall G; Rycroft W; Macleod AM
    J Med Chem; 2004 Nov; 47(24):5829-32. PubMed ID: 15537339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.
    Atack JR; Eng WS; Gibson RE; Ryan C; Francis B; Sohal B; Dawson GR; Hargreaves RJ; Burns HD
    Br J Pharmacol; 2009 Jul; 157(5):796-803. PubMed ID: 19422390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of extra-synaptic α5-GABA
    Etherington LA; Mihalik B; Pálvölgyi A; Ling I; Pallagi K; Kertész S; Varga P; Gunn BG; Brown AR; Livesey MR; Monteiro O; Belelli D; Barkóczy J; Spedding M; Gacsályi I; Antoni FA; Lambert JJ
    Neuropharmacology; 2017 Oct; 125():353-364. PubMed ID: 28807671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.